Dyslipidemia and abdominal obesity: Therapeutic approaches (Part II)
Point Médical, dijon.Archives des maladies du coeur et des vaisseaux (Impact Factor: 0.4). 01/2008; 100(12):985-7, 990-1.
Lifestyle changes form the basis of the therapeutic management of dyslipidemia associated with abdominal obesity and other risk factors associated with an excess of visceral adipose tissue. The use of lipid-lowering agents is justified if the therapeutic objectives are not attained by lifestyle changes alone. New therapeutic approaches are aimed directly at the excess visceral adipose tissue, and the CB1 receptor blockers are particularly promising for improving the overall lipid profile for patients with abdominal obesity.